気管支拡張薬の世界市場：薬剤クラス別、投与経路別、適応症別、流通チャネル別、地域別

気管支拡張薬の世界市場は、2025年には228億7,000万米ドルと推定され、2032年には296億9,000万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は3.8%で成長する見込みです。

図.気管支拡張薬の世界市場シェア（%）、2025年地域別

気管支拡張薬は、肺の気道を広げて呼吸を楽にする薬です。気管支拡張薬は、気管支を取り囲む平滑筋を弛緩・拡張させることで作用し、喘鳴、咳、息切れ、その他喘息や慢性閉塞性肺疾患（COPD）などの呼吸器疾患に伴う症状を軽減します。気管支拡張薬には、突然の息苦しさの発作を短期的に緩和するために使用される短時間作用型のものと、喘息やCOPDの息苦しさをコントロールし、喘息における副腎皮質ステロイド薬の効果を高めるために定期的に使用される長時間作用型のものがあります。抗コリン薬（抗ムスカリン薬としても知られる）は、主にCOPDの治療に使用されるが、一部は喘息にも使用できます。抗コリン薬はコリン作動性神経を遮断することで気道を広げます。気管支拡張薬の副作用は、特定の薬によって異なります。気管支拡張薬の一般的な副作用には、特に手の震え、頭痛、筋肉のけいれん、吐き気や嘔吐、下痢などがあります。

市場力学：

世界の気管支拡張薬市場の成長を牽引しているのは、呼吸器疾患にかかりやすい高齢者人口の増加、都市部・農村部双方における環境汚染レベルの上昇、喘息やCOPDの適切な管理に関する意識の高まりといった要因です。しかし、代替治療オプションの利用可能性、気管支拡張薬の長期使用に伴う副作用、ブロックバスター薬の特許切れなどが、市場成長を抑制すると予想される主な要因の一部です。2種類以上の薬剤を同時に投与できる併用療法の開発は、この市場の企業に新たな機会をもたらしています。さらに、呼吸器症状をよりよく管理するための予防的吸入療法がより重視されるようになり、将来の需要を牽引すると思われます。

本調査の主な特徴

• 本レポートは、世界の気管支拡張薬市場を詳細に分析し、2024年を基準年とした予測期間（2025年～2032年）の市場規模および複合年間成長率（CAGR）を提供します。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 本レポートでは、気管支拡張薬の世界市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要製品ハイライト、財務実績、戦略などのパラメータに基づいて掲載しています。主な対象企業は、GSK plc.、アストラゼネカ、マイランN.V.、メルク社、サン・ファーマシューティカル・インダストリーズ社、グレンマーク社、ノバルティスAG、ベーリンガーインゲルハイム・インターナショナル社、テバ・ファーマシューティカル・インダストリーズ社、シプラ社、サノビオン・ファーマシューティカルズ社、サノフィ社、イノビバ社などです。
• このレポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 気管支拡張薬の世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の気管支拡張薬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 製品承認の向上
  • 厳格な規制環境
  • 啓発キャンペーンの強化
• 主なハイライト
• 規制シナリオ
• 市場動向
• パイプライン分析
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 疫学
• 治療アルゴリズム（ペイシェントジャーニー）
• 治療オプション分析
• 主要市場プレーヤーによる新規投資
• 価格分析
• 疾病啓発プログラム
• 治療の安全性と有効性の分析
• 合併、買収、および提携

第4章 世界の気管支拡張薬市場-COVID-19パンデミックの影響

• COVID-19疫学
• 供給側と需要側の分析
• 経済への影響

第5章 世界の気管支拡張薬市場、薬剤クラス別、2020年～2032年

• ベータアドレナリン性気管支拡張薬
• キサンチン誘導体
• 抗コリン性気管支拡張薬

第6章 世界の気管支拡張薬市場、投与経路別、2020年～2032年

• 経口
• 鼻腔（吸入可能）
• 注射剤

第7章 世界の気管支拡張薬市場、適応症別、2020年～2032年

• 喘息
• 慢性閉塞性肺疾患（COPD）
• その他（慢性気管支炎など）

第8章 世界の気管支拡張薬市場、流通チャネル別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 世界の気管支拡張薬市場、地域別、2020年～2032年

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東
• アフリカ

第10章 競合情勢

• 企業プロファイル
  • GSK plc.
  • Mylan NV
  • Mylan NV
  • Merck &Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Sunovion Pharmaceuticals Inc.
  • Sanofi
  • Innoviva

第11章 セクション

• 参考文献
• 調査手法
• 出版社について

Global Bronchodilators Market is estimated to be valued at USD 22.87 Bn in 2025 and is expected to reach USD 29.69 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.8% from 2025 to 2032.

Figure. Global Bronchodilators Market Share (%), By Region 2025

Bronchodilators are medications that help open up the airways in the lungs to allow for easier breathing. They work by relaxing and dilating the smooth muscles surrounding the bronchial tubes, thus reducing wheezing, coughing, shortness of breath and other symptoms associated with respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be either short-acting used as short-term relief from sudden, unexpected attacks of breathlessness or long-acting used regularly to help control breathlessness in asthma and COPD, and increase the effectiveness of corticosteroids in asthma. Anticholinergics (also known as antimuscarinics) are mainly used to treat COPD, but a few can also be used for asthma. Anticholinergics cause the airways to widen by blocking the cholinergic nerves. The side effects of bronchodilators can vary, depending on the specific medication. General side effects of bronchodilators include trembling, particularly in the hands, headache, muscle cramps, nausea and vomiting, diarrhea, etc.

Market Dynamics:

The global bronchodilators market growth is driven by factors such as the growing geriatric population which is more susceptible to respiratory diseases, increased environmental pollution levels in both urban and rural areas, and rising awareness about proper management of asthma and COPD. However, availability of alternative treatment options, side effects associated with long term use of bronchodilators, and patent expires of blockbuster drugs are some of the key factors expected to restrain market growth. Development of combination therapies that can deliver two or more drugs simultaneously is opening new opportunities for players in this market. Moreover, greater emphasis on preventive inhalation therapies for better management of respiratory symptoms will drive future demand.

Key features of the study:

• This report provides in-depth analysis of the global bronchodilators market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bronchodilators market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global bronchodilators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchodilators market

Detailed Segmentation:

• Global Bronchodilators Market, By Drug Class
  • Beta-adrenergic Bronchodilators
  • Xanthine Derivatives
  • Anticholinergic Bronchodilators
• Global Bronchodilators Market, By Route of Administration
  • Oral
  • Nasal (inhalable)
  • Injectable
• Global Bronchodilators Market, By Indication
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others (Chronic bronchitis, etc.)
• Global Bronchodilators Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Bronchodilators Market, By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles
  • GSK plc.
  • AbbVie Inc.
  • AstraZeneca
  • Mylan N.V.
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Sunovion Pharmaceuticals Inc.
  • Sanofi
  • Innoviva

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Indication
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing Product Approval
  • Stringent Regulatory Environment
  • Increasing Awareness Campaigns
• Key Highlights
• Regulatory Scenario
• Market Trends
• Pipeline Analysis
• Product Launch/Approval
• PEST Analysis
• PORTER's Analysis
• Epidemiology
• Treatment Algorithm (Patient Journey)
• Treatment Option Analysis
• New Investments by Major Market Players
• Pricing Analysis
• Disease Awareness Programs
• Treatment Safety and Efficacy Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Bronchodilators Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Bronchodilators Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Beta-adrenergic Bronchodilators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Xanthine Derivatives
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Anticholinergic Bronchodilators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global Bronchodilators Market, By Route of Administration, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Nasal (inhalable)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Global Bronchodilators Market, By Indication, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Asthma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Chronic Obstructive Pulmonary Disease (COPD)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others (Chronic bronchitis, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Bronchodilators Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 201s9-2032, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

9. Global Bronchodilators Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profile
  • GSK plc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Mylan N.V.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Mylan N.V.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Merck & Co., Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Sun Pharmaceutical Industries Ltd.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Glenmark Pharmaceuticals Limited
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Novartis AG
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Boehringer Ingelheim International GmbH
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Teva Pharmaceutical Industries Ltd.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Cipla Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Sunovion Pharmaceuticals Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Sanofi
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Innoviva
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Analyst Views

11. Section

• References
• Research Methodology
• About us